New drug combo shows promise in early cancer trial
NCT ID NCT05378425
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug called NTX-1088, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 90 adults with cancers like lung, colorectal, or melanoma are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Hadassah Medical Center
Jerusalem, 9574425, Israel
-
Maria Skłodowska-Curie National Research Institute of Oncology
Warsaw, Poland
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Sheba Medical Center
Ramat Gan, 5262131, Israel
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.